News from nektar therapeutics A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 30, 2015, 16:15 ET

Nektar Therapeutics Reports Financial Results for the First Quarter of 2015

 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2015. Cash and investments in...

Apr 23, 2015, 16:15 ET

Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2015 on Thursday, April 30, 2015,...

Apr 16, 2015, 09:14 ET

Baxter Submits Application To Japan's MHLW For Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A

 Nektar Therapeutics (NASDAQ:NKTR) reported today that partner Baxter International Inc. announced that the company has submitted a new drug...

Apr 13, 2015, 16:15 ET

Nektar Therapeutics to Present at the 14th Annual Needham Healthcare Conference

 Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the 14th Annual Needham...

Apr 02, 2015, 09:35 ET

Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca

 Nektar Therapeutics (NASDAQ: NKTR) announced today that it has received a $100 million payment under a license agreement with AstraZeneca. The...

Mar 31, 2015, 09:10 ET

MOVANTIK™ (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Launched In The US

Nektar Therapeutics (NASDAQ: NKTR) reported that partner AstraZeneca announced today that MOVANTIK™ (naloxegol) has launched in the United...

Mar 19, 2015, 08:30 ET

AstraZeneca And Daiichi Sankyo To Jointly Commercialise MOVANTIK In The US

Nektar Therapeutics (NASDAQ: NKTR) reported that partner AstraZeneca today announced a co-commercialisation agreement with Daiichi Sankyo, Inc. for...

Mar 17, 2015, 16:15 ET

Etirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival by 2.1 Months versus Active Control in Patients with Advanced Breast Cancer in Phase 3 Study; Trial Did Not Achieve Statistical Significance (p=0.08)

 Nektar Therapeutics (NASDAQ: NKTR) today announced topline results from its Phase 3 BEACON study evaluating single-agent NKTR-102 in patients...

Feb 25, 2015, 09:26 ET

Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain

 Nektar Therapeutics (NASDAQ: NKTR) today announced the enrollment of the first patient in SUMMIT-07, its initial Phase 3 study of...

Feb 24, 2015, 16:10 ET

Nektar Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2014. Cash and...

Feb 17, 2015, 16:15 ET

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2014 on Tuesday, February 24, 2015, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2014 on Tuesday, February...

Feb 11, 2015, 09:11 ET

Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A

Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc. today presented additional efficacy and safety data from the...

Jan 06, 2015, 08:30 ET

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

 Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 33rd...

Dec 11, 2014, 18:00 ET

Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer

Nektar Therapeutics (NASDAQ: NKTR) today presented biomarker data from a sub-study of the Phase 3 BEACON study of etirinotecan pegol (NKTR-102)...

Dec 09, 2014, 08:00 ET

MOVENTIG® Approved In The European Union For Opioid-Induced Constipation

 Nektar Therapeutics (NASDAQ:NKTR) reported partner AstraZeneca today announced that MOVENTIG® (naloxegol) has been granted Marketing...

Nov 20, 2014, 09:00 ET

Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model

Nektar Therapeutics (NASDAQ: NKTR) today announced results of a study investigating the preclinical anti-tumor activity and tolerability of...

Nov 06, 2014, 16:10 ET

Nektar Therapeutics Reports Financial Results for the Third Quarter of 2014

 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2014. Cash and investments...

Oct 30, 2014, 08:30 ET

Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2014 on Thursday, November 6,...

Sep 26, 2014, 07:30 ET

Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation

 Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the Committee for Medicinal Products for Human Use...

Sep 19, 2014, 09:00 ET

Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting

 Nektar Therapeutics (NASDAQ:NKTR) today announced results from preclinical studies characterizing the analgesic profiles of a series of the...